Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2014; 20(25): 8195-8200
Published online Jul 7, 2014. doi: 10.3748/wjg.v20.i25.8195
Published online Jul 7, 2014. doi: 10.3748/wjg.v20.i25.8195
Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients
Gong-Ying Chen, Meng-Fei Zhu, Jie Wang, Guo-Qiang Lou, Hospital Affiliated to Hangzhou Normal University, Hangzhou 310015, Zhejiang Province, China
Da-Liang Zheng, Yan-Ting Bao, Xiang Zhou, the Sixth Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou 310012, Zhejiang Province, China
Author contributions: Chen GY and Zhu MF contributed equally to this work; Lou GQ and Chen GY designed the research; Zhu MF, Zheng DL and Bao YT performed the research; Wang J and Zhou X analyzed the data; Chen GY wrote the manuscript.
Supported by the Natural Science Foundation of Zhejiang Province, China, No. Y210435
Correspondence to: Dr. Guo-Qiang Lou, Hospital Affiliated to Hangzhou Normal University, 126 Wenzhou Road, Hangzhou 310015, Zhejiang Province, China. louguoqiang2008@126.com
Telephone: +86-571-88063403 Fax: +86-571-88021730
Received: October 30, 2013
Revised: January 16, 2014
Accepted: April 5, 2014
Published online: July 7, 2014
Revised: January 16, 2014
Accepted: April 5, 2014
Published online: July 7, 2014
Core Tip
Core tip: The response to antiviral therapy in chronic hepatitis B (CHB) patients varies significantly among individuals. This retrospective study of 55 patients evaluated the predictive effect of baseline hepatitis B surface antigen (HBsAg) on virological response in HBeAg-positive CHB patients treated with pegylated interferon (PEG-IFN)-α2b. The results suggest that baseline HBsAg level in combination with HBV DNA quantitative values may become an effective predictor for guiding optimal therapy with PEG-IFN-α2b against HBeAg-positive CHB.